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Background
The design of gp120 monomeric probes with modified
antigenic profiles that are specific for a target epitope has
been successfully used for the isolation of broadly neutra-
lizing HIV-1 antibodies. Existing probes, however, do not
possess sufficient specificity and can bind antibodies with
undesired properties (e.g., weakly neutralizing antibodies
targeting an overlapping epitope). To achieve improved
epitope specificity, positive and negative design stages can
be incorporated into the probe design process.
Methods
Here, we apply a combination of structure- and sequence-
based methods for improving the epitope specificity of
gp120 monomeric probes. Specifically, structure-based
redesign using the OSPREY protein design software suite
was used to predict gp120 knock-out mutations for
selected antibodies. Additionally, using a sequence-based
mutual information approach, knock-out mutations were
designed by identifying gp120 residues that are predicted
to associate with neutralization resistance for a given
antibody.
Results
Using stabilized (Ds12F123) and resurfaced stabilized
(RSC3) HXB2 gp120 cores as templates, we designed a set
of mutants with improved epitope specificity. In particular,
RSC3 (a prototypic probe previously used for the isolation
of VRC01 and other CD4-binding-site antibodies) was
redesigned to specifically bind CD4-binding-site antibodies
that are broadly neutralizing (VRC01, VRC-PG04: positive
design) but not moderately/weakly neutralizing (b12, b13,
HJ16: negative design). Additionally, CD4i-specific probes
were designed by introducing mutations that destabilize
binding to the entire class of CD4-binding-site antibodies
(negative design), while retaining binding to CD4i antibo-
dies (positive design). The desired epitope specificity of
the redesigned probes was confirmed by ELISA binding.
The probe design approach was further validated with
knock-out mutations for a diverse set of antibodies,
including PG9 and 2F5.
Conclusion
Probes with enhanced epitope specificity can select more
precisely for antibodies with desired properties. A set of
our redesigned probes are currently being utilized for the
isolation of antibodies targeting different epitopes of inter-
est on the HIV-1 Envelope.
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